Are Analysts Bearish Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) After Last Week?

August 11, 2017 - By Clifton Ray

 Are Analysts Bearish Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) After Last Week?

Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Ratings Coverage

Among 6 analysts covering Summit Therapeutic (NASDAQ:SMMT), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Summit Therapeutic had 8 analyst reports since August 19, 2015 according to SRatingsIntel. The stock has “Buy” rating by Oppenheimer on Wednesday, August 19. The firm earned “Buy” rating on Thursday, June 15 by Canaccord Genuity. H.C. Wainwright initiated the shares of SMMT in report on Friday, September 16 with “Buy” rating. Zacks downgraded the stock to “Hold” rating in Tuesday, September 1 report. H.C. Wainwright maintained the shares of SMMT in report on Thursday, July 6 with “Buy” rating. Oppenheimer maintained Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) rating on Thursday, June 22. Oppenheimer has “Buy” rating and $2400 target. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 16. The rating was initiated by Janney Capital on Tuesday, June 21 with “Buy”. Below is a list of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) latest ratings and price target changes.

06/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $26.0000 Maintain
22/06/2017 Broker: Oppenheimer Rating: Buy New Target: $24.0000 Maintain
15/06/2017 Broker: Canaccord Genuity Rating: Buy New Target: $28.0000 Maintain

The stock increased 2.61% or $0.33 on August 11, reaching $12.98. About 9,869 shares traded. Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has risen 33.22% since August 11, 2016 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The company has market cap of $156.68 million. The Firm is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It currently has negative earnings. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.